文献速递湿疹皮炎与荨麻疹毛发、甲与色素性疾病银屑病与炎症性皮肤病

65岁及以上成人使用JAK抑制剂:特应性皮炎、斑秃和银屑病的临床综述

Janus Kinase Inhibitor Use in Adults Aged 65 Years and Older: A Clinical Review Across Atopic Dermatitis, Alopecia Areata, and Psoriasis.
PubMed 文献 · J Am Acad Dermatol · 2026-09-24

该临床综述综合3期试验、安全性分析、真实世界队列及FDA/EMA标签中按年龄分层的证据,评估JAK抑制剂在65岁及以上成人特应性皮炎、斑秃和银屑病中的疗效与安全性。结论认为JAK抑制剂对经仔细选择的老年患者可能是合理选择,但需基于疾病特异性疗效、基线心血管和肿瘤风险、可干预合并症、标签指导剂量及密切监测进行个体化决策。

要点

  • 特应性皮炎:upadacitinib 15 mg和abrocitinib 100 mg对老年患者有效,通常避免更高剂量。
  • 斑秃:baricitinib在小样本老年队列显示疗效,ritlecitinib在该年龄组数据有限。
  • 银屑病:deucravacitinib提供持久应答且无MACE或VTE黑框警告,催化性JAK抑制剂需按标签给药并密切监测。

核心结论

  • JAK抑制剂对经仔细选择的65岁及以上成人可能是合理选择,但决策应审慎,基于疾病特异性疗效、基线心血管和肿瘤风险、可干预合并症、标签指导剂量及密切监测。
  • 年龄分层数据仍稀少,每项决策应个体化。

研究设计与样本

  • 临床综述,综合3期试验、整合安全性分析、真实世界队列及FDA/EMA标签中按年龄分层的结局,形成实践建议(补充附录1B)。

主要发现

  • 特应性皮炎中,upadacitinib 15 mg和abrocitinib 100 mg对老年患者有效,通常避免更高剂量。
  • 斑秃中,baricitinib在小样本老年队列显示疗效,ritlecitinib在该年龄组数据过于有限,无法得出年龄特异性结论。
  • 银屑病中,deucravacitinib提供持久应答且避免MACE或VTE黑框警告,用于银屑病关节炎的催化性JAK抑制剂需按标签指导剂量并密切监测。

关键数值与推荐

  • 特应性皮炎:upadacitinib 15 mg和abrocitinib 100 mg有效,通常避免更高剂量。
  • 银屑病:deucravacitinib提供持久应答且无MACE或VTE黑框警告。
  • 催化性JAK抑制剂用于银屑病关节炎需标签指导剂量和密切监测。

临床怎么用

  • 对65岁及以上成人处方JAK抑制剂应审慎决策,评估疾病特异性疗效、基线心血管和肿瘤风险及可干预合并症。
  • 按标签指导剂量用药并密切监测,尤其使用催化性JAK抑制剂时。

局限性

  • 65岁及以上成人在JAK抑制剂临床试验中代表性不足。
  • 年龄分层数据仍稀少,ritlecitinib在老年斑秃患者中数据过于有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: JAK inhibitors are increasingly used as systemic therapies for inflammatory dermatoses, but adults aged 65 and older are underrepresented in their clinical trials. OBJECTIVE: To synthesize the efficacy, safety, and regulatory evidence on JAK inhibitors in adults aged 65 and older with atopic dermatitis, alopecia areata, and psoriasis. METHODS: Clinical review synthesizing phase 3 trials, integrated safety analyses, real-world cohorts, and FDA/EMA labeling with age-stratified outcomes into practice recommendations (Supplementary Appendix 1B). RESULTS: In atopic dermatitis, upadacitinib 15 mg and abrocitinib 100 mg are effective in older adults, with higher doses generally avoided. In alopecia areata, baricitinib shows efficacy in small older-adult cohorts, while ritlecitinib data in this age group remain too limited for age-specific conclusions. In psoriasis, deucravacitinib provides durable responses and avoids boxed warnings for MACE or VTE, while catalytic JAK inhibitors for psoriatic arthritis need label-directed dosing and close monitoring. CONCLUSION: JAK inhibitors may be a reasonable option for carefully selected older adults, but the decision should be a deliberate one. It rests on disease-specific efficacy, baseline cardiovascular and oncologic risk, modifiable comorbidities, label-directed dosing, and close monitoring. Age-stratified data remain sparse, and each decision should be individualized.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Ezzat RZ, Paz M, Kreytak C, et al. Janus Kinase Inhibitor Use in Adults Aged 65 Years and Older: A Clinical Review Across Atopic Dermatitis, Alopecia Areata, and Psoriasis. J Am Acad Dermatol. 2026. PMID: 42785684. doi:10.1016/j.jaad.2026.09.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。